Such idea that tumor-targeted delivery of the CD47 checkpoint antagonist can work as a potential booster to synergize with other tumor-targeting antibodies for better cancer immunotherapy is being actively investigated, as reflected by phase I clinical trials testing its combination therapy with cetuximab or rituximab (Table 1). The gene discussed is CD47; the disease is neoplasm.